Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2024 · 10-Q
Revenue$22.15M$22.15M−1.8% vs Q1 2023 Net Income-$492.00K-$492.00KN/M vs Q1 2023 EPS Diluted-$0.01-$0.01N/M vs Q1 2023 Gross Profit$13,456,000−0.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow$295,000−89.4% Margins · derivedGross margin60.7%+0.8 pt vs Q1 2023
Operating margin-3.3%+5.4 pt vs Q1 2023
Net margin-2.2%+6.2 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end